Logo of archdischfnArchives of Disease in Childhood - Fetal & NeonatalVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Arch Dis Child Fetal Neonatal Ed. Nov 1997; 77(3): F185–F190.
PMCID: PMC1720712

Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants


AIM—To determine whether treatment with inhaled nitric oxide (NO) and/or dexamethasone reduces the incidence of chronic lung disease (CLD) and/or death in high risk preterm infants.
METHODS—Infants below 32 weeks of gestation were recruited at 96 hours of age if they were deemed to be at high risk of developing CLD. Infants were randomly assigned to one of four treatment groups using a factorial design: (1) 5-20 parts per million inhaled NO for 72 hours; (2) 0.5-1 mg/kg/day intravenous dexamethasone for 6 days; (3) both drugs together; (4) continued conventional management.
RESULTS—Forty two infants were randomised: 10 infants received inhaled NO alone; 11 dexamethasone alone; 10 both treatments; and 11 neither treatment. There was no difference in the combined incidence of CLD and/or death before discharge from hospital between either infants treated with inhaled NO and controls (RR 1.05, 95% CI 0.84-1.25), or those treated with dexamethasone and controls (RR 0.95, 95% CI 0.79-1.18).
CONCLUSIONS—At 96 hours of age, neither treatment with inhaled NO nor dexamethasone prevented CLD or death.

Keywords: randomised controlled trial; nitric oxide; dexamethasone; chronic lung disease

Full Text

The Full Text of this article is available as a PDF (109K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Shaw N, Gill B, Weindling M, Cooke R. The changing incidence of chronic lung disease. Health Trends. 1993;25(2):50–53. [PubMed]
  • Abman SH, Kinsella JP. Inhaled nitric oxide therapy of pulmonary hypertension and respiratory failure in premature and term neonates. Adv Pharmacol. 1995;34:457–474. [PubMed]
  • Rastogi A, Akintorin SM, Bez ML, Morales P, Pildes RS. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics. 1996 Aug;98(2 Pt 1):204–210. [PubMed]
  • Yeh TF, Torre JA, Rastogi A, Anyebuno MA, Pildes RS. Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. J Pediatr. 1990 Aug;117(2 Pt 1):273–282. [PubMed]
  • Rozé JC, Storme L, Zupan V, Morville P, Dinh-Xuan AT, Mercier JC. Echocardiographic investigation of inhaled nitric oxide in newborn babies with severe hypoxaemia. Lancet. 1994 Jul 30;344(8918):303–305. [PubMed]
  • Sanders RJ, Cox C, Phelps DL, Sinkin RA. Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Pediatr Res. 1994 Jul;36(1 Pt 1):122–128. [PubMed]
  • Shinwell ES, Karplus M, Zmora E, Reich D, Rothschild A, Blazer S, Bader D, Yurman S, Dolfin T, Kuint J, et al. Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 1996 Jan;74(1):F33–F37. [PMC free article] [PubMed]
  • Ryan SW, Nycyk J, Shaw BN. Prediction of chronic neonatal lung disease on day 4 of life. Eur J Pediatr. 1996 Aug;155(8):668–671. [PubMed]
  • Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988 Oct;82(4):527–532. [PubMed]
  • Iyer P, Evans N. Re-evaluation of the left atrial to aortic root ratio as a marker of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed. 1994 Mar;70(2):F112–F117. [PMC free article] [PubMed]
  • Cooke RW. Early and late cranial ultrasonographic appearances and outcome in very low birthweight infants. Arch Dis Child. 1987 Sep;62(9):931–937. [PMC free article] [PubMed]
  • Finer NN, Etches PC, Kamstra B, Tierney AJ, Peliowski A, Ryan CA. Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response. J Pediatr. 1994 Feb;124(2):302–308. [PubMed]
  • Bührer C, Merker G, Falke K, Versmold H, Obladen M. Dose-response to inhaled nitric oxide in acute hypoxemic respiratory failure of newborn infants: a preliminary report. Pediatr Pulmonol. 1995 May;19(5):291–298. [PubMed]
  • Abman SH, Kinsella JP, Schaffer MS, Wilkening RB. Inhaled nitric oxide in the management of a premature newborn with severe respiratory distress and pulmonary hypertension. Pediatrics. 1993 Oct;92(4):606–609. [PubMed]
  • Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992 Oct 3;340(8823):819–820. [PubMed]
  • Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992 Oct 3;340(8823):818–819. [PubMed]
  • Barefield ES, Karle VA, Phillips JB, 3rd, Carlo WA. Inhaled nitric oxide in term infants with hypoxemic respiratory failure. J Pediatr. 1996 Aug;129(2):279–286. [PubMed]
  • Roberts JD, Jr, Fineman JR, Morin FC, 3rd, Shaul PW, Rimar S, Schreiber MD, Polin RA, Zwass MS, Zayek MM, Gross I, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med. 1997 Feb 27;336(9):605–610. [PubMed]
  • Barnes PJ. Nitric oxide and airway disease. Ann Med. 1995 Jun;27(3):389–393. [PubMed]
  • Kavanagh BP, Mouchawar A, Goldsmith J, Pearl RG. Effects of inhaled NO and inhibition of endogenous NO synthesis in oxidant-induced acute lung injury. J Appl Physiol (1985) 1994 Mar;76(3):1324–1329. [PubMed]
  • Kubes P, Granger DN. Nitric oxide modulates microvascular permeability. Am J Physiol. 1992 Feb;262(2 Pt 2):H611–H615. [PubMed]
  • Mulligan MS, Hevel JM, Marletta MA, Ward PA. Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6338–6342. [PMC free article] [PubMed]
  • Evans NJ, Archer LN. Doppler assessment of pulmonary artery pressure and extrapulmonary shunting in the acute phase of hyaline membrane disease. Arch Dis Child. 1991 Jan;66(1 Spec No):6–11. [PMC free article] [PubMed]
  • Evans NJ, Archer LN. Doppler assessment of pulmonary artery pressure and extrapulmonary shunting in the acute phase of hyaline membrane disease. Arch Dis Child. 1991 Jan;66(1 Spec No):6–11. [PMC free article] [PubMed]
  • Högman M, Frostell C, Arnberg H, Hedenstierna G. Bleeding time prolongation and NO inhalation. Lancet. 1993 Jun 26;341(8861):1664–1665. [PubMed]
  • Heal CA, Spencer SA. Methaemoglobinaemia with high-dose nitric oxide administration. Acta Paediatr. 1995 Nov;84(11):1318–1319. [PubMed]
  • Foubert L, Fleming B, Latimer R, Jonas M, Oduro A, Borland C, Higenbottam T. Safety guidelines for use of nitric oxide. Lancet. 1992 Jun 27;339(8809):1615–1616. [PubMed]

Articles from Archives of Disease in Childhood. Fetal and Neonatal Edition are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...